Literature DB >> 20632326

Prospective comparison of two flow cytometry methodologies for monitoring minimal residual disease in a multicenter treatment protocol of childhood acute lymphoblastic leukemia.

Drorit Luria1, Eti Rosenthal, David Steinberg, Yona Kodman, Marina Safanaiev, Ninette Amariglio, Smadar Avigad, Batia Stark, Shai Izraeli.   

Abstract

BACKGROUND: Minimal residual disease (MRD) is a powerful prognostic indicator in childhood acute lymphoblastic leukemia (ALL). Multiparametric flow cytometry (FC) is a rapid and sensitive methodology for detection of MRD, applicable for most patients and is being incorporated in multicenter treatment protocols. The influence of different techniques and of individual interpretation of data on the interlaboratory variability in FC-MRD determinations has not been described.
METHODS: We compared FC-MRD of identical bone marrow samples processed as either Ficoll separated mononuclear cells or lyse and wash nucleated cells (NC) in two central laboratories of a national multicenter childhood ALL study. A total of 290 samples at diagnosis and 494 follow-up samples (Day-15 n = 261; Day-33 n = 233) were analyzed. A group of 52 paired list mode data (LMD) of D-15 and D-33 samples was blindly reanalyzed by both laboratories.
RESULTS: Pearson correlations for all samples of D-15 (n = 261) and D-33 (n = 233) were 0.875 and 0.82, respectively (P < 0.001), being lower for T-ALL 0.716 and 0.719, respectively. Quantitative concordance defined as less than 0.5 log difference in MRD measured by the two methodologies was 80.8% at D-15 but only in 57.9% at D-33. Reanalysis of LMD revealed that data interpretation explained half of the discordance.
CONCLUSIONS: FC-MRD analysis of childhood ALL is a robust method during the earliest phases of induction therapy in a multicentric setting. Standardization of data analysis could improve about half of the discordance between different technical approaches.
© 2010 International Clinical Cytometry Society.

Entities:  

Mesh:

Year:  2010        PMID: 20632326     DOI: 10.1002/cyto.b.20532

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  7 in total

1.  Detection of minimal residual disease in B lymphoblastic leukemia using viSNE.

Authors:  Joseph A DiGiuseppe; Michelle D Tadmor; Dana Pe'er
Journal:  Cytometry B Clin Cytom       Date:  2015-06-02       Impact factor: 3.058

Review 2.  Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care?

Authors:  Dario Campana
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

Review 3.  Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders.

Authors:  Gaurav Chatterjee; Sumeet Gujral; Papagudi G Subramanian; Prashant R Tembhare
Journal:  Indian J Hematol Blood Transfus       Date:  2017-04-26       Impact factor: 0.900

Review 4.  Minimal residual disease in acute lymphoblastic leukemia: optimal methods and clinical relevance, pitfalls and recent approaches.

Authors:  Fatemeh Salari; Mohammad Shahjahani; Saeid Shahrabi; Najmaldin Saki
Journal:  Med Oncol       Date:  2014-10-07       Impact factor: 3.064

Review 5.  Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.

Authors:  Juliana Maria Camargos Rocha; Sandra Guerra Xavier; Marcelo Eduardo de Lima Souza; Juliana Godoy Assumpção; Mitiko Murao; Benigna Maria de Oliveira
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-04-10       Impact factor: 2.576

6.  Multiparametric Whole Blood Dissection: A one-shot comprehensive picture of the human hematopoietic system.

Authors:  Luca Basso-Ricci; Serena Scala; Raffaella Milani; Maddalena Migliavacca; Attilio Rovelli; Maria Ester Bernardo; Fabio Ciceri; Alessandro Aiuti; Luca Biasco
Journal:  Cytometry A       Date:  2017-06-13       Impact factor: 4.355

7.  Measurements of treatment response in childhood acute leukemia.

Authors:  Dario Campana; Elaine Coustan-Smith
Journal:  Korean J Hematol       Date:  2012-12-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.